Alibaba launches open-source AI coding model, touted as its most advanced to date
The model is designed for high-performance software development and touted as its most advanced AI coding model to date.
The model excels in agentic AI coding tasks, from generating new codes and managing complex coding workflows, according to the statement.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Nvidia (NVDA) Boosts H20 Chip Orders to Meet Soaring Chinese Demand
NVIDIA Corporation (NASDAQ:NVDA) is one of the . On July 29, Reuters reported that Nvidia has placed orders for 300,000 H20 chipsets with contract manufacturer TSMC last week driven by Chinese demand. The increased demand has led the U.S. firm to change its mind about just relying on its existing stockpile. The Trump administration recently reversed its ban on exporting H20 chips to China. Nvidia had developed the H20 particularly for the Chinese market after U.S. imposed export restrictions on its other AI chipsets. The H20 has less computing power as Nvidia's H100 or its new Blackwell series sold in markets outside China. A busy Wall Street trader typing orders into a financial terminal. Sources reveal that the new orders would add to the current 600,000 to 700,000 H20 chips that Nvidia has currently. According to U.S. research firm SemiAnalysis, Nvidia sold 1 million H20 chips in 2024. While Nvidia still needs to obtain export licenses from the U.S. government to ship said H20 chips, it has been assured by authorities that it would get them soon. NVIDIA Corporation (NASDAQ:NVDA) specializes in AI-driven solutions, providing high-performance GPUs and platforms that power data centers, autonomous vehicles, robotics, and cloud services. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Apple's (AAPL) AI Strategy Falls Short, Says Barclays—Is the Stock Still a Must-Watch?
Apple Inc. (NASDAQ:AAPL) is one of the . On July 29, Barclays said it remains cautious on Apple, maintaining its 'Underweight' rating. The analyst highlighted factors such as limited traction on artificial intelligence and risks around tariffs, China, and regulation. The firm said that it anticipates 'a slight June-Q beat led by better FX, iPhone and Mac upside,' helped by tariff-related pull-in. It isn't very optimistic on the stock due to a lack of progress. 'We still see no major progress on AI for AAPL.' Particularly discussing Apple's innovations at the annual developer conference, the firm said that the conference 'underwhelmed with the AI feature announcements, viewing them as more evolutionary than revolutionary.' It further added that 'The reception of Apple Intelligence has also been disappointing.' The firm believes Apple's long-term AI strategy remains muddy and that its light weight approach to AI may or may not be enough to drive an upgrade cycle or growth. Barclays also talked about tariffs, stating that '2H GM remains a wildcard with lack of clarity on tariffs and mitigation efforts.' Apple is a technology company known for its consumer electronics, software, and services. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate
Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company reported sales of $2.65 billion, up 7% year over year on a reported basis, 8% on constant currency, beating the consensus of $2.32 billion. Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Sales of the multiple sclerosis drug Tysabri were down to $454.6 million from $462.2 disease revenue increased 2% year over year (up 3% on constant currency) to $543 million. Spinraza's revenue decreased to $392.7 million from $429.1 million a year ago. Revenues from Skyclarys, acquired via the Reata acquisition, reached $130.3 million during the quarter, up from $100 million a year ago, showing continued growth in demand; U.S. SKYCLARYS revenue of approximately $78 million represents sequential growth of 13%. In Alzheimer's disease, Biogen said Leqembi's U.S. in-market sales of approximately $63 million represent sequential growth of 20%. Global in-market sales of approximately $160 million include a one-time shipment to China of approximately $35 million to optimize global inventory levels. Clinical data presented at AAIC demonstrate that four years of continuous treatment with Leqembi benefits early Alzheimer's patients, including low tau patients, who continue to see sustained improvements in cognitive and daily living function. Outlook Biogen raised its 2025 adjusted earnings guidance from $14.50-$15.50 per share to $15.50-$16.00, compared to the consensus of $14.98. View more earnings on BIIB The updated guidance reflects an 87 cents benefit from an expected stronger business outlook for the full year, partially offset by the ~($0.12) impact from the City Therapeutics transaction. The company expects total revenue for the full year 2025 to be approximately flat, at constant currency, versus the full year 2024, which is up from a mid-single digit decline previously. The outlook reflects the strong first-half revenue performance, including the resilient performance of the U.S. multiple sclerosis business. Biogen expects increased competitive pressures on the ex-U.S. multiple sclerosis business in the second half of 2025, particularly for Tecfidera in Europe. Due to planned plant maintenance activities, Biogen expects minimal contract manufacturing revenue in the fourth quarter of 2025. Potential tariffs, even if the current exemption for pharmaceuticals ends, are not expected to affect the company's 2025 financial outlook. The Fit for Growth program is expected to generate approximately $1 billion of gross savings and $800 million net of reinvestment by the end of 2025. In 2025, Biogen plans to make additional investments in R&D, primarily to support rare diseases. Biogen expects combined Non-GAAP R&D expense and Non-GAAP SG&A expense to total approximately $4 billion in 2025. Price Action: BIIB stock is trading higher by 3.01% to $130.45 at last check Thursday. Read Next:Photo by JHVEPhoto via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? BIOGEN (BIIB): Free Stock Analysis Report This article Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
